Gilead loses key patent challenge over best-selling HIV drug
Gilead won’t easily rid of itself of this HIV patent challenge.
Last year, the Department of Health and Human Services said that it owned some of the patents for Gilead’s best-selling HIV prevention drug, Truvada, also known as PrEP. Gilead responded by arguing in court that HHS’s patents were invalid.
Today, a US Patent and Trademark Office panel ruled that Gilead was likely to lose its challenge.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.